Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Heart Failure
100%
Implantable Defibrillator
96%
Extended Follow-up
72%
National Cohort Study
71%
Long-run Risk
63%
Hazard Ratio
60%
Cardioverter-defibrillator Implantation
60%
Ischemic Heart Failure
54%
Ischemic Stroke
46%
Atrial Fibrillation
45%
Non-ischemic Systolic Heart Failure
44%
Heart Failure with Preserved Ejection Fraction (HFpEF)
40%
All-cause Mortality
39%
Confidence Interval
35%
Adverse Cardiovascular Events
35%
Sudden Cardiovascular Death
29%
Thrombolysis
26%
Background Population
22%
Long-term Rate
21%
Comorbidity
21%
Incident Heart Failure
19%
1-year Mortality
19%
Autoimmune Disease
19%
Acute Coronary Syndrome
17%
Sarcoidosis
17%
Cardiac Outcomes
17%
Patients with Heart Failure
17%
Cardiovascular Mortality
16%
Nationwide Registry
16%
First Year
16%
Hospitalization
13%
Non-ischemic
13%
Ventricular Arrhythmia
12%
Odds Ratio
12%
Cardiovascular Outcomes
12%
Usual Care
11%
Primary Prevention
11%
Cardiac Resynchronization Therapy
11%
Acute Ischemic Stroke
11%
ICD Implantation
11%
Mortality Rate
10%
Denmark
10%
Systemic Lupus Erythematosus
10%
New York Heart Association Functional Class
10%
Chronic Kidney Disease
9%
Risk Factors
9%
Control Subjects
9%
Mortality Hazard
9%
Risk of Death
9%
Long-term Cardiovascular Outcomes
9%
Medicine and Dentistry
Implantable Automatic Defibrillator
97%
Cardiovascular System
74%
Hazard Ratio
48%
Heart Failure
46%
Atrial Fibrillation
41%
Heart Failure with Reduced Ejection Fraction
40%
Congestive Heart Failure
36%
Heart Muscle Ischemia
35%
Systolic Heart Failure
33%
Cohort Analysis
31%
Brain Ischemia
31%
Acute Coronary Syndrome
17%
Blood Clot Lysis
17%
Chronic Kidney Disease
13%
Defibrillator
11%
Heart Ventricle Arrhythmia
11%
Systemic Lupus Erythematosus
10%
Combination Therapy
9%
Cause of Death
9%
Autoimmune Disease
9%
New York Heart Association Class
9%
Systemic Scleroderma
9%
Brain Natriuretic Peptide
8%
Takotsubo Cardiomyopathy
8%
Heart Right Ventricle Function
8%
Sarcoma
8%
Sphingosine 1 Phosphate
8%
Granulomatosis with Polyangiitis
8%
Apolipoprotein M
8%
Subacute Cutaneous Lupus Erythematosus
8%
Heart Tumor
8%
Sarcoidosis
8%
Exercise
8%
Glomerular Filtration Rate
8%
Amino Terminal Sequence
8%
Nursing Home
8%
Antithrombotic
8%
Population
8%
Noncardiac Surgery
8%
Thyroid Function
8%
Amyloidosis
8%
Lumbar Spinal Stenosis
8%
Patient History of Surgery
8%
Frailty
8%
All Cause Mortality
8%
Primary Prevention
7%
Malignant Neoplasm
7%
Proportional Hazards Model
7%
Mortality Rate
6%
Ejection Fraction
5%
Pharmacology, Toxicology and Pharmaceutical Science
Heart Failure
78%
Cohort Study
48%
All Cause Mortality
45%
Brain Ischemia
41%
Systolic Heart Failure
41%
Atrial Fibrillation
34%
Comorbidity
25%
Heart Failure with Reduced Ejection Fraction
22%
Autoimmune Disease
19%
Congestive Heart Failure
18%
Sarcoidosis
17%
Heart Muscle Ischemia
17%
Symptom
15%
Heart Ventricle Arrhythmia
13%
Systemic Lupus Erythematosus
10%
Cause of Death
9%
Combination Therapy
9%
Systemic Sclerosis
9%
Population Study
9%
Brain Natriuretic Peptide
8%
Nonischemic Cardiomyopathy
8%
Takotsubo Cardiomyopathy
8%
Acute Coronary Syndrome
8%
Fibrinolytic Agent
8%
Syndrome
8%
Wegener Granulomatosis
8%
Skin Lupus Erythematosus
8%
Dermatomyositis
8%
Polymyositis
8%
Disease
8%
Statin (Protein)
8%
Antivitamin K
8%
Anticoagulant Agent
8%
Coronavirinae
8%
Anticoagulation Therapy
8%
Frailty
8%
Overall Survival
8%
Mortality Rate
5%
ST Segment Elevation Myocardial Infarction
5%
Infection
5%
